Patients with tumor antigen-specific T‐cell response showed significantly higher levels of HMGB1 at the end of treatment compared to patients without this specific T‐cell response, probably indicating better anti-tumor immune responses possibly related to better tumor control. The gene discussed is HMGB1; the disease is neoplasm.